This is in line with findings in moderate breast cancer risk genes such as CHEK2, PALB2 and ATM [44–46] and suggests that PRS inclusion in risk stratification may in particular be relevant to prevent excess of surveillance measures in PV carriers of those genes. The gene discussed is CHEK2; the disease is breast carcinoma.